Comparing the current results to its competitors, Travere Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 55.63 % year on year. The sales growth was above Travere Therapeutics Inc 's competitors' average revenue growth of 8.29 %, achieved in the same quarter.
Travere Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 151.04 %
Travere Therapeutics Inc 's Comment on Competition and Industry Peers
The pharmaceutical and biotechnology industries are highly competitive, with many larger and better-resourced companies. Competition is particularly intense in the development and commercialization of new products for rare diseases, where major pharmaceutical, biotechnology, and specialty pharmaceutical companies invest significantly in orphan drug discovery and development. Key competitive factors include speed of development, clinical testing, regulatory approval, product efficacy, safety, reliability, availability, price, reimbursement, patent position, and regulatory exclusivity. FILSPARI (Sparsentan) received full FDA approval on September 5, 2024, for slowing kidney function decline in adults with primary IgAN. It is the only oral, once-daily, non-immunosuppressive medication that targets glomerular injury by blocking two critical pathways of IgAN disease progression.
Due to outstanding performance in Overall company, revenue grew by 55.63 % Travere Therapeutics Inc improved its market share, to approximately 0.33 %.
October 17, 2025
: Travere Therapeutics, Inc. (Nasdaq: TVTX) is poised to make significant announcements during the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, from November 6-9. With 11 abstracts slated for presentation, including a notable late-breaking poster, the company highlights key developments in advanced treatments for focal segmental glomerulosclerosis (FSGS), with a focus on the efficacy of FILSPARI (sparsentan).Focal segmental glomerulosclerosis (FSGS) remains a challenging condition that leads to progressive kidney disease and poses treatment dilemmas. As researchers and clinicians gather at ASN Kidney Week 2025, Travere Therapeutics aims to elucidate the clinical benefits of their lea...
August 28, 2025
: The recent U.S. Food and Drug Administration (FDA) approval of the updated Risk Evaluation and Mitigation Strategy (REMS) for FILSPARI (sparsentan) a key therapeutic agent for IgA nephropathy (IgAN) marks a significant advancement in both patient safety and the operational framework of Travere Therapeutics, Inc. This article explores the implications of the REMS modification alongside recent financial metrics that indicate the company’s evolving leverage dynamics. On October 17, 2023, Travere Therapeutics, Inc. (Nasdaq: TVTX) announced a pivotal approval from the U.S. FDA regarding a modification to the Risk Evaluation and Mitigation Strategy (REMS) associated with FILSPARI (sparsentan). Recognised as...
October 17, 2024
Travere Therapeutics Inc. in collaboration with CSL Vifor, has officially announced that their investigational drug, FILSPARI (sparsentan), has received approval from Swissmedic for the treatment of IgA nephropathy. This significant milestone marks an important advancement in the therapeutic options available for patients suffering from this kidney disease.IgA nephropathy is a chronic and progressive disease characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, leading to inflammation and potential kidney damage. The condition can result in serious health consequences, including end-stage renal disease (ESRD) in some patients. With the approval of FILSPARI, a novel oral therapy that tar...
October 13, 2024
In the dynamic landscape of biopharmaceutical investments, the currents of regulatory scrutiny and market performance coalesce to shape investor sentiment and corporate reputations. Recent developments surrounding Travere Therapeutics, Inc. (NASDAQ: TVTX) underscore this intersection as Bronstein, Gewirtz and Grossman, LLC announces an investigative effort to explore potential claims on behalf of the company’s shareholders.As of October 13, 2024, the legal firm has publicly encouraged those who have purchased Travere securities to contribute insights that may further inform the investigation. This announcement comes at a pivotal time, given Travere Therapeutics current performance metrics, which reveal a ...
October 1, 2024
The biotechnology industry, characterized by its rapid innovations and significant breakthroughs, is not without its challenges. One such challenge is the scrutiny it faces from investors, regulatory bodies, and legal firms. Travere Therapeutics, Inc. (NASDAQ: TVTX) has recently come under the legal microscope as Bronstein, Gewirtz and Grossman, LLC, a prominent law firm, has announced an investigation into potential claims on behalf of the company s investors. This development raises critical questions about the company s operational and financial status and holds significant implications for its stakeholders. The Investigation Unfurled The law firm Bronstein, Gewirtz and Grossman, LLC, with a reputation fo...
March 13, 2024
Travere Therapeutics, Inc. recently disclosed the issuance of inducement equity grants to four newly hired employees. This move aligns with the company s compensation strategy and complies with Nasdaq Listing Rule 5635(c)(4). The grants, comprising stock options and restricted stock units (RSUs), were awarded outside of Travere s 2018 Equity Incentive Plan, yet are bound by its terms. This article delves into the details of these grants and explores their implications for Travere s workforce and potential investors.Key Facts:1. On March 10, 2024, Travere Therapeutics Compensation Committee approved inducement equity grants, covering a total of 51,600 common stock shares.2. The grants were allocated to four ...
January 25, 2024
Travere Therapeutics, a leading biopharmaceutical company, has recently entered into an exclusive licensing agreement with Renalys Pharma. This collaboration aims to develop and commercialize sparsentan, a breakthrough therapy for kidney patients, in the countries of Japan, South Korea, Taiwan, and Southeast Asian nations. The partnership comes as great news, offering hope and improved treatment options for patients in these regions.1. Sparsentan: A Novel Therapy for Kidney Diseases:Sparsentan, developed by Travere Therapeutics, is a novel investigational therapy that shows promising potential in treating kidney diseases. It combines both endothelin receptor antagonism and angiotensin receptor blockade, prov...
Travere Therapeutics Inc recently conducted a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA) for FILSPARI in IgA nephropathy (IgAN). The meeting was fruitful, and as a result, the company intends to submit a supplemental New Drug Application (sNDA) to the FDA in the first quarter of 2024. This submission aims to convert the existing U.S. accelerated approval of FILSPARI (sparsentan) in IgAN to full approval. The pre-NDA meeting is a crucial step in the drug approval process as it allows the company to present relevant data and discuss the potential regulatory pathway with the FDA. Obtaining full approval for FILSPARI in IgAN would be a significant milesto...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Travere Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Travere Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
